High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: A retrospective investigation on 133 patients treated in a single institution

2011 ◽  
Vol 86 (9) ◽  
pp. 762-767 ◽  
Author(s):  
Antonio Azzarà ◽  
Giovanni Carulli ◽  
Sara Galimberti ◽  
Claudia Baratè ◽  
Rita Fazzi ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
Single Agent ◽  
High Dose ◽  
Intermediate Risk ◽  
Single Institution ◽  
Human Erythropoietin ◽  
Retrospective Investigation

High-Dose Recombinant Human Erythropoietin Administered Intravenously for the Treatment of Anaemia in Myelodysplastic Syndromes

1992 ◽  
Vol 87 (1) ◽  
pp. 25-27 ◽  
Author(s):  
N. Casadevall ◽  
C. Belanger ◽  
A. Goy ◽  
B. Varet ◽  
J. Lang ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
High Dose ◽  
Human Erythropoietin

Hemodynamic effects of recombinant human erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model

2008 ◽  
Vol 109 (6) ◽  
pp. 1155-1164 ◽  
Author(s):  
Amanda M. Murphy ◽  
Anargyros Xenocostas ◽  
Pria Pakkiri ◽  
Ting-Yim Lee
Keyword(s):  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Subarachnoid Hemorrhage ◽  
Recombinant Human Erythropoietin ◽  
Low Dose ◽  
Saline Group ◽  
High Dose ◽  
Hemodynamic Effects ◽  
Neurological Outcomes ◽  
Human Erythropoietin

Object The authors investigated the hemodynamic effects of recombinant human erythropoietin (rhEPO) after subarachnoid hemorrhage (SAH) in rabbits. Methods The authors used male New Zealand White rabbits in this study divided into the following groups: SAH plus saline (16 rabbits), SAH plus low-dose rhEPO (16 rabbits; 1500 IU/kg on Day 0 and 500 IU/kg on Days 2 and 4), SAH plus high-dose rhEPO (10 rabbits; 1500 IU/kg on Days 0, 2, 4, and 6), and sham (6 rabbits). Computed tomography perfusion studies and CT angiography were performed for 1 hour after SAH on Day 0, and once each on Days 2, 4, 7, 9, and 16 after SAH. Assessments of neurological function and tissue histology were also performed. Results The mortality rate was significantly lower after rhEPO treatment (12%) than after saline treatment (44%) (p < 0.05). Neurological outcomes in the low-dose and high-dose rhEPO groups were better than in the saline group after SAH (p < 0.05), and the cerebral blood flow in the high-dose rhEPO group was greater than that in the saline group (p < 0.05). The mean transit time was significantly lower on Days 2 and 4 in the low-dose and high-dose rhEPO groups than in the saline group, but increased significantly on Day 7 in both groups (p < 0.05). The hematocrit increased significantly from baseline values in the high-dose and low-dose rhEPO groups on Days 4 and 7, respectively (p < 0.05). Conclusions Treatment with rhEPO after experimental SAH is associated with improved cerebral blood flow and microcirculatory flow as reflected by lower mean transit times. Improved tissue perfusion correlated with reduced mortality and improved neurological outcomes. Further investigation of the impact of increasing hematocrit on hemodynamic changes is needed.

Effectiveness of Recombinant Human Erythropoietin Therapy in Myelodysplastic Syndromes

1992 ◽  
Vol 87 (1) ◽  
pp. 20-24 ◽  
Author(s):  
J.W. Adamson ◽  
M. Schuster ◽  
S. Allen ◽  
N.R. Haley
Keyword(s):  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment

1992 ◽  
Vol 64 (1) ◽  
pp. 16-21 ◽  
Author(s):  
G. E. G. Verhoef ◽  
P. Zachée ◽  
A. Ferrant ◽  
H. Demuynck ◽  
D. Selleslag ◽  
...  
Keyword(s):  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document